Current Diabetes Reports

, Volume 6, Issue 1, pp 47-54

First online:

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

  • Susanne TrostAffiliated withDiabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine Email author 
  • , Richard E. Pratley
  • , Burton E. Sobel

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.